AbbVie
ABBV Big PharmaImmunology and oncology specialist spun from Abbott in 2013. Humira successor portfolio includes Skyrizi and Rinvoq. Expanded into aesthetics via Allergan acquisition.
FDA Novel Drug Designations
(2016-2025)AbbVie at a Glance
- Leading 6 drug targets across portfolio
- Fast trial execution (25 months median completion)
Upcoming FDA Decisions
Full Calendar →AbbVie's Key Drugs
AbbVie's core commercial portfolio centers on SKYRIZI, RINVOQ, VENCLEXTA, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.
Moderate-to-severe plaque psoriasis
Moderately to severely active rheumatoid arthritis
Chronic lymphocytic leukemia (CLL)
Schizophrenia
Irritable Bowel Syndrome
AbbVie's Recent FDA Approvals
AbbVie secured 4 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
AbbVie's Therapeutic Areas
AbbVie's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Oncology, across 5 biologic and 53 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AbbVie's Top Competitors
AbbVie's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Roche, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AbbVie Pipeline Snapshot
AbbVie has 664 active clinical programs from ClinicalTrials.gov — 248 Phase 3, 172 Phase 2 and 244 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 168/252 completed
- • Speed: 25 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (22)
Discontinued (9)
Company Info
- First Approval
- 1944-07-31
- Latest
- 2026-08-19
- Applications
- 225
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges